Fortis Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

Fortis Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,502	Closed	-$65K	–	311
2017 Q3	$65K	Buy	+3,502	New	+$65.3K	0.05%	152

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fortis Advisors's AMAG Position: Q4 2017 in Review

Fortis Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2017, closing a stake of 3,502 shares — an estimated $65K sold.

Fortis Advisors first reported a position in AMAG in Q3 2017 and held it in 1 quarter. The position peaked at $65K in Q3 2017. 170 funds tracked by Wall St. Rank hold AMAG as of Q4 2017.

Fortis Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Fortis Advisors sold 3,502 AMAG Pharmaceuticals shares in Q4 2017, an estimated $65K.
Fortis Advisors first reported a position in AMAG Pharmaceuticals in Q3 2017 and held it in 1 quarter.
Fortis Advisors's AMAG Pharmaceuticals position peaked at $65K in Q3 2017.
170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2017.

Based on Fortis Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.